Weekly Round-up #145
We are excited to bring you yet another packed VALIDATE Weekly Round-up this week.
VALIDATE Now Ends November 2021!
In excellent news, VALIDATE has been awarded a six month no-cost extension by our funders, the MRC & BBSRC, due to the impact of the COVID-19 pandemic on our activities and projects. With this extension, VALIDATE will be able to support its members until 30 November 2021, which is fantastic.
If you have any thoughts about what activities VALIDATE should host in 2021, or how Team VALIDATE can support you over the next 12 months, get in touch at firstname.lastname@example.org.
Upcoming VALIDATE Events
A quick reminder that although there are only a few weeks to go in 2020, we have a packed events schedule. Our December talks are all open access and online, making them accessible from around the world, so do please spread the word to colleagues, collaborators and even school kids - anyone interested in our members and their research is welcome:
- BCG vaccination of infants confers Mycobacterium tuberculosis strain-specific immune responses by leukocytes, Subbian S et al, in ACS Infectious Diseases
- Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis, Tiwari RK et al, in International Immunopharmacology
- Overexpression of the celA1 gene in BCG modifies surface pellicle, glucosamine content in biofilms, and affects in vivo replication, Vaca-González A et al, including VALIDATE member Mario Alberto Flores-Valde, in Tuberculosis
- Tuberculosis vaccination needs to avoid ‘decoy’ immune reactions, Ivanyi J, in Tuberculosis
Published: 02 December 2020